Tissue Regenix Ltd (TRL) was established in May 2006 and is dedicated to the development of clinical solutions to address the chronic shortfalls in donor tissue availability in areas such as Vascular and Orthopaedic medicine.
There is a well established clinical need for more donor tissue for many surgical procedures. Tissue Regenix will develop and commercialise acellular tissue repair products to meet this need, to ultimately benefit patients.
The key features of TRL's dCell™ products are:
- Similar functional and response characteristics to native tissue
- Compatibility with all blood and cell types
- Reduced calcification
- Similar biomechanical properties
- Regenerate in vivo
|
